A recent meta-analysis by Dimitriadis et al (2024)[54] also revealed that long-term use of SGLT2 inhibitors clearly reduced the risk of CIN in patients with type 2 diabetes undergoing PCI. The gene discussed is SLC5A2; the disease is cervical squamous intraepithelial neoplasia.